Elgemtumab

Drug Profile

Elgemtumab

Alternative Names: LJM-716; NOV-6

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator MorphoSys; Novartis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Oesophageal cancer
  • Phase I Solid tumours
  • No development reported Breast cancer; Gastric cancer; Head and neck cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Breast-cancer in Canada (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Breast-cancer in South Korea (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Breast-cancer in Spain (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top